Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
ApexOnco Front Page
Recent articles
But now it must show that varseta-M can move into a registrational trial.
Pfizer cans PF-08046045, but keeps PF-08046044 for now.
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
Syndax’s Revuforj beats Kura in NPM1-mutated AML.
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
